Transgelin induces apoptosis of human prostate LNCaP cells through its interaction with p53

Asian Journal of Andrology

Volumn 12, Issue 2, 2010, Pages 186-195

  Zhang, Zhe Wei ^a   Yang, Zhi Ming ^b   Zheng, Yi Chun ^a   Chen, Zhao Dian ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Apoptosis; Mitochondria; P53; Prostate cancer; Transgelin

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE PROTEIN; PROTEIN ARA54; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PUMA PROTEIN; TRANSGELIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; NICK END LABELING; PROSTATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU NICK-END LABELING; MALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77749324160     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.76     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2: 389-96.
3. Kent EC, Hussain MH. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 2003; 62 (Suppl 1): 134-40.
4. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 2003; 62: 21-6.
5. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60: 132-8; discussion 138-9.
6. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology 2005; 65: 9-16; discussion 17.
7. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324-6.
8. Vander Griend DJ, Litvinov I V, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007; 6: 647-51.
9. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1647-51.
10. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53.
11. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189: 559-63.
12. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
13. Heinlein CA, Chang C. Androgen receptor (AR) coregu-lators: an overview. Endocr Rev 2002; 23: 175-200.
14. Heemers HV, Tindall DJ. Androgen receptor (AR) coregu-lators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
15. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004; 18: 2633-48.
16. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7: 523-35.
17. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, et al. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002; 277: 4609-17.
18. Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 2004; 24: 1044-57.
19. Kang HY, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 1999; 274: 8570-6.
20. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007; 21: 343-58.
21. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-30.
22. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-83.
23. Kastan MB. Wild-type p53: tumours can't stand it. Cell 2007; 128: 837-40.
24. Wang W, El-Deiry WS. Restoration of p53 to limit tumour growth. Curr Opin Oncol 2008; 20: 90-6.
25. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2: 113-6.
26. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999; 161: 304-8.
27. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995; 55: 3726-31.
28. Cohen MB, Rokhlin OW. Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 2009; 106: 363-71.
29. Lees-Miller JP, Heeley DH, Smillie LB. An abundant and novel protein of 22 kDa (SM22) is widely distributed in smooth muscles. Purification from bovine aorta. Biochem J 1987; 244: 705-9.
30. Kobayashi R, Kubota T, Hidaka H. Purification, characterization, and partial sequence analysis of a new 25-kDa actin-binding protein from bovine aorta: a SM22 homolog. Biochem Biophys Res Commun 1994; 198: 1275-80.
31. Shapland C, Hsuan JJ, Totty NF, Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993; 121: 1065-73.
32. Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumours and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002; 277: 9790-9.
33. Yeo M, Kim DK, Park HJ, Oh TY, Kim JH, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 2006; 6: 1158-65.
34. Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007; 13: 348-53.
35. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32: 284-93.
36. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-12.
37. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65: 2108-14.
38. Assinder SJ, Stanton JA, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009; 41: 482-6.
39. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 849-62.
40. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6: 443-50.
41. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-90.